Combined-Modality Therapy With Gemcitabine and Radiotherapy As a Bladder Preservation Strategy: Results of a Phase I Trial
Elizabeth C. Kent(National Oceanography Centre), David C. Smith(University of Michigan), Howard M. Sandler(Cedars-Sinai Medical Center), James E. Montie(University of Michigan), Joseph M. Herman(Northwell Health), Peg Esper(University of Michigan), Judith Fardig(University of Michigan), Cheryl Lee(Agency for Science, Technology and Research)
Cited by 86
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2015|1.2k
Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study
|Science Translational Medicine|2011|637